Cellular stress and inflammation with miniature cardiopulmonary bypass

Does mini-cardiopulmonary bypass (CPB) reduce cellular stress and inflammation compared with standard CPB?

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN30610605

Enrollment

Registered

2010-05-12

Start date

2010-06-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Cardiovascular

Interventions

All patients referred for primary elective coronary artery bypass grafting (CABG) will be considered for inclusion within the clinical trial. Trial participants will be randomised into one of three di

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age range 18+ years 2. No gender discrimination 3. Patients referred for elective coronary artery bypass grafting (CABG) 4. Not participated in any other clinical trial

Exclusion criteria

Exclusion criteria: 1. Patients less than 18 years of age 2. Emergency cases 3. Combined valvular procedures 4. Redo operations 5. Poor left ventricular function (ejection fraction less than 30%) 6. Cerebro-vascular accident within 3 months pre-operatively or more than 75% carotid artery obstruction as shown by carotid Doppler scan 7. Serum creatinine in excess of 177 µmol/L 8. Pre-existing coagulopathy 9. Pre-existing liver dysfunction 10. Recent (within 5 days) use of antiplatelets (aspirin/clopidogrel)

Design outcomes

Primary

Measure	Time frame
Blood parameters of cellular stress - reactive oxygen species detection; p38 MAP kinase signalling	—

Secondary

Measure	Time frame
Supporting conventional markers of the inflammatory response will be measured including white cell count	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 20, 2026